Tislelizumab as monotherapy or in sequential combination with lenvatinib for neoadjuvant treatment of resectable hepatocellular carcinoma: A prospective, phase II clinical study. NEO-ERA-01: A ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results